NEW YORK (GenomeWeb News) – Saladax Biomedical today announced the appointment of Kaan Medikal as the exclusive distributor of the Saladax My5-FU diagnostic test in Turkey for measuring levels of a commonly used chemotherapy for colorectal cancer.
My5-FU, the first commercially available dose management test from Saladax, measures levels of 5-flourouracil (5-FU), which is used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. Saladax said that its assay technology allows oncologists to determine the proper dose of 5-FU for patients, increasing the drug's effectiveness while limiting the risk of severe toxicity and other side effects.
Interest in Turkey for My5-FU is strong "and we expect that Kaan Medikal's market leadership in diagnostic testing and excellent reputation for quality will enable significant opportunities for growth, which will translate into improved care for patients undergoing chemotherapy treatment for colorectal and other solid tumor cancers," Adrienne Choma, vice president of marketing and sales for Saladax, said in a statement.
Financial and other terms of the deal were not disclosed.
In June, Bethlehem, Pa.-based Saladax completed a $9 million debt financing with GE Capital to support commercialization of the My5-FU assay and to develop additional assays.